β-catenin degrader

Disease Need

Mutations in the Wnt/β-catenin pathway are responsible for millions of cases of cancer globally every year, but to date there have been no successful therapies targeting this pathway. These mutations are particularly prevalent in colorectal cancer: An estimated 80-90% of cases of colorectal cancer are caused by mutations in the Wnt/β-catenin pathway.^[1]

To fully realize the rich array of monotherapy and combination approaches possible by directly targeting β-catenin we have expanded our drug discovery efforts beyond FOG-001. With this goal in mind, we are developing β-catenin degrader Helicon™ candidates, which offer an alternative mechanistic approach to addressing the Wnt/β-catenin pathway.

Our Approach

The β-catenin degrader uses our Helicon technology to bind to soluble β-catenin and target it to the proteasome for degradation using a bifunctional degrader approach.